Drug Trial Radar · NCT04947319
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
119
Actual
Start
Dec 29, 2021
Primary completion
Jan 27, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Conditions
- Refractory Primary Central Nervous System Lymphoma
- Primary CNS Lymphoma
Interventions
TirabrutinibDrug
Part A: Tirabrutinib 480 mg, taken orally, once a day on an empty stomach. Tirabrutinib treatment may be continued until disease progression or clinically unacceptable toxicity is observed.
TirabrutinibDrug
Part B, Arm 1 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an MTR induction regimen. Tirabrutinib with MTR treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed. For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment.
TirabrutinibDrug
Part B, Arm 2 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an R-MPV induction regimen. Tirabrutinib with R-MPV treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed. For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR) (Part A)Time frame: 1 year
- Tirabrutinib dose estimate (Part B)Time frame: 1 month
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) during induction (Part B)Time frame: 4 months
- Complete response rate (CRR) (Part B)Time frame: 4 months
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham School of Medicine
Birmingham, Alabama
Mayo Clinic- Phoenix
Phoenix, Arizona
City of Hope Comprehensive Breast Cancer Center
Duarte, California
University of California, Irvine
Irvine, California
Stanford University
Palo Alto, California
University of Colorado Denver
Aurora, Colorado
Yale Cancer Center
New Haven, Connecticut
Georgetown University, Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia
Mayo Clinic- Jacksonville
Jacksonville, Florida
University of Miami-Sylvester Cancer Center
Miami, Florida
Orlando Health
Orlando, Florida
Moffitt Cancer Center- Miami
Pembroke Pines, Florida
Piedmont Healthcare
Atlanta, Georgia
University of Kentucky
Lexington, Kentucky
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute - Brigham & Women's Hospital
Boston, Massachusetts
University Of Michigan
Ann Arbor, Michigan
Henry Ford Hospital
Detroit, Michigan
The University of Kansas Cancer Center (KUCC) (Kansas City Cancer Center (KCCC)) - North
Kansas City, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Hackensack University Medical Center - John Theurer Cancer
Hackensack, New Jersey
Roswell Park Comprehensive Cancer Center (RPCCC) (Roswell Park Cancer Institute (RPCI))
Buffalo, New York
Memorial Sloan Kettering
New York, New York
Columbia University Irving Medical Center
New York, New York
Levine Cancer Center
Charlotte, North Carolina
Duke University School of Medicine
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
Providence Health Cancer Center
Portland, Oregon
Penn State Hershey Cancer Center
Hershey, Pennsylvania
Abramson Cancer Center University of Pennsylvania
Philadelphia, Pennsylvania
Hillman Cancer Center, University of Pittsburgh
Pittsburgh, Pennsylvania
Lifespan Rhode Island Hospital
Providence, Rhode Island
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Houston Methodist Research Institute (HMRI)
Houston, Texas
MD Anderson Cancer Center
Houston, Texas
The University of Utah - Huntsman Cancer Institute (HCI)
Salt Lake City, Utah
The University of Vermont - Fletcher Allen Health Care
Burlington, Vermont
Seattle Cancer Care Alliance
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.